LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) — Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it will release second quarter 2023 financial results on Thursday, August 3, 2023, after the market close. Following the release of its financial results, Assertio’s management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
To access the live webcast, conference call information, and other materials, please visit Assertio’s investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wishing to join by telephone only, please dial +1-929-201-5912.
A webcast replay of the call will be available approximately two hours after the call on Assertio’s investor website.
About Assertio
Assertio is a specialty pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. We have built and continue to build our commercial portfolio by identifying new opportunities within our existing products as well as acquisitions or licensing of additional approved products. To learn more about Assertio, visit www.assertiotx.com.
Investor Contact
Matt Kreps
Darrow Associates Investor Relations
+1-214-597-8200
mkreps@darrowir.com
SUNNYVALE, Calif., May 28, 2025 /PRNewswire/ -- Imagine starting every dental appointment with an AI-generated…
Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF)…
CAROLINA, Puerto Rico, May 27, 2025 /PRNewswire/ -- CorePlus, a leading precision pathology organization in…
SAN ANTONIO, Texas--(BUSINESS WIRE)--AirStrip, a leader in vendor-agnostic clinical surveillance and decision support technologies, today…
Burlington, Ontario--(Newsfile Corp. - May 27, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT"…
Findings Released in ASCO Abstract Validate Life-Saving Impact of AION TempShield’s Long-Term Temperature Tracking for…